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The ability to measure concentrations ofcocaine in body fluids can contribute substantially to
any investigation of cocaine's pharmacological effects. Design of research which involves the
administration of cocaine must take into account current knowledge regarding the drug's
pharmacokinetics. Cocaine's very rapid elimination from the body should be considered in
attempting to understand patterns ofcocaine abuse, and such phenomena as bingeing and acute
tolerance. Accurate analysis of cocaine and/or its metabolites is essential to the diagnosis and
evaluation of cocaine use whether for medical or forensic purposes. Appropriate selection of
methods for analysis of cocaine depends upon the intended purpose of the assay, and correct
interpretation of the data obtained upon knowledge of cocaine's kinetics and metabolic disposi-
tion.
The measurement of cocaine and its metabolites has considerable relevance to
cocaine research, both clinical and basic, and to that controversial and fuzzy interface
between medicine and social policy defined as drug abuse screening. Investigations of
the clinical effects of cocaine, and the differing consequences of various routes of
administration, are clearly enhanced by the ability to determine concentrations of
cocaine and its time course within the body. Any attempt to develop a method for the
analysis ofbody fluids to detect use or abuse ofcocaine, whether for clinical or forensic
purposes, and any attempt to obtain intelligible information from the data obtained,
also require knowledge ofcocaine's metabolic disposition and ofits pharmacokinetics.
METABOLIC DISPOSITION OF COCAINE
With its low concentrations in body fluids, very rapid and complete metabolic
disposition, and susceptibility to enzymatic and spontaneous hydrolysis both in vivo
and in vitro, accurate measurement of cocaine represents an interesting challenge to
the toxicologist and pharmacologist. If cocaine is incubated with human plasma or
with liver homogenates, it is rapidly hydrolyzed with formation of ecgonine methyl
ester, one ofcocaine's two major metabolites [1-4]. We were initially concerned with
this aspect because of our need to preserve cocaine for future analysis in plasma
samples obtained from experimental subjects. We found that the addition of sodium
fluoride or physostigmine to plasma prevented its decomposition, suggesting that
serum cholinesterase was responsible. We alsoobserved that sera from subjects who by
history were sensitive to succinylcholine, and whose dibucaine numbers indicated that
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they were either homozygous or heterozygous for inheritance of the atypical esterase,
failed to hydrolyze cocaine or hydrolyzed it at an intermediate rate, respectively [1].
Similar findings were reported by Stewart et al. [3], who also demonstrated that
cocaine was metabolized by liver homogenates to the same product. While the
homozygous state for inheritance of the atypical enzyme occurs with a frequency of
only about 1 in 2,500, about 4 percent ofthe population are heterozygous. The relative
importance ofserum cholinesterase and other liver esterases in the actualdisposition of
cocaine in vivo has not been established. An intriguing question that remains
unanswered is whether or not individuals who either have reduced activity of the
normal cholinesterase, or who have inherited the atypical form, are at increased risk
for toxicity or fatal overdose following cocaine use, especially following the extremely
large cumulative doses that are administered during binges. Chronic liver disease and
pregnancy are events in the drug-abusing population that can reduce activity of
cholinesterase, aside from inheritance ofthe atypical enzyme.
Cleavage ofthe methyl ester group yields benzoylecgonine, which is the other major
metabolite of cocaine. This compound is of particular interest because most cocaine
immunoassays used for urine drug screening employ an antibody directed at benzoyl-
ecgonine rather than the parent compound. This method is used because very little
unchanged cocaine is excreted in the urine, while approximately 50 percent of an
administered dose of cocaine appears in the urine as benzoylecgonine. It has been
suggested that spontaneous chemical hydrolysis may be responsible for the appearance
of this metabolite [3], and, as yet, an enzymatic pathway for the formation of
benzoylecgonine has not been identified.
Approximately 85-90 percent ofan administered doseofcocaine is recovered in the
urine, only about 1-5 percent of which is eliminated as the unchanged parent
compound. About 75-90 percent is eliminated as ecgonine methyl ester and benzoylec-
gonine combined [5-8]. Both of these metabolites are inactive as regards their ability
to block the re-uptake of monoamines into presynaptic neurons and the production of
pharmacological effects in animals.
Hepatic mixed function oxidases play only a minor role in the metabolic disposition
of cocaine in humans, although they are more important in some other species.
N-demethylation of cocaine in hepatic microsomes produces norcocaine, the only
pharmacologically active metabolite of cocaine as yet identified [9]. Although very
little norcocaine is produced in humans, this microsomal pathway is ofsome interest in
that it can result in theformation ofhepatotoxic-reactive intermediate metabolite(s) in
some species of rodents [10-13]. Although hepatotoxicity as a direct consequence of
cocaine use has not been demonstrated in humans, its occurrence is difficult to
discriminate in the framework of polydrug and alcohol abuse and a high incidence of
hepatitis.
PHARMACOKINETICS
The rate ofappearance ofcocaine in the blood varies, as might be expected, with the
route of administration. Following intravenous or pulmonary (smoking-"crack" or
freebase) administration, relatively high peak plasma levels are achieved almost
instantaneously [14-16]. Systemic bioavailability by the smoking route, if only that
cocaine that reaches the respiratory tract is considered, appears to be excellent [16].
Some users state that smoking cocaine produces qualitatively different and/or more
intense effects. The intravenous route is, however, considered to be a reasonable
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paradigm for cocaine smoking, but with more precise and predictable dosage control.
Smoking, on the other hand, provides a noninvasive way to achieve instant access of
cocaine to the systemic circulation. Peak plasma levels after intravenous use or
smoking of the usual doses appear to be in the range of about 500-1,000 ng/ml [14].
Peak concentrations achieved during binges have not been established but, based upon
anecdotal reports ofthe quantities consumed, may be considerably higher.
Freebase, which can be volatilized at relatively low temperature, is the more potent
dosage form, and that most widely employed by smokers. Cocaine is a tertiary amine
with a pKa of 8.6. At higher pHs the un-ionized or freebase form predominates, while
at more acidic pH cocaine exists as a salt, e.g., hydrochloride. Traditionally, the
freebasewas prepared by alkalinizing an aqueous solutionofthesaltandextracting the
freebase into an organic solvent such as ether, which was then evaporated. Crack, on
the other hand, is prepared by precipitating cocaine from an alkalinized aqueous
solution. This innovative and relatively simple street technique for preparation of the
freebase avoids the use of organic solvents, with their attendant risks, and associated,
sometimes spectacular, accidents. In any event, once in the systemic circulation,
cocaine is in the same form, regardless of route of administration or type of dosage
preparation.
The first cocaine plasma levels were obtained in surgical patients who received
intranasal drug for vasoconstriction and local anesthesia prior to intubation [7].
Cocaine can be detected in the blood very soon after intranasal dosing, but peak levels
do not occur until about one hour after administration. Vasoconstriction limits the rate
of absorption of cocaine, and thus variable amounts are swallowed. One of the more
interesting, although in retrospect not that surprising, outcomes ofour studies was the
finding that cocaine is absorbed and pharmacologically active following oral adminis-
tration [18]. In this instance, cocaine appears in the plasma following a lag phase of
about 30 minutes.
Andean natives have for years self-administered cocaine by chewing coca leaves.
This form ofadministration is associated with sustained absorption, in contrast to the
intermittent administration typical of street use. Plasma cocaine concentrations in
samples obtained from Andean natives chewing coca leaves according to their usual
custom are in the same range as those seen after administration of modest doses of
crystalline cocaine by the oral or intranasal routes [19]. Cocaine's systemic bioavail-
ability by the intranasal and oral routes has been described as 20-60 percent in various
reports [20,21]. Peak plasma levels after the "usual" intranasal dosages are in the
rangeofabout 100-500 ng/ml [20].
The quality and intensity of cocaine's psychotropic effects vary with route of
administration apparently as a function of differences in absorption kinetics or rate of
rise in plasma levels [22,23]. Moreover, pharmacological effects associated with any
given level of cocaine are greater during the ascending portion of the plasma level vs.
time curve than while concentrations are falling [24-27]. This clockwise hysteresis
curve is characteristic ofacute tolerance [28] and may have relevance to patterns and
consequences of cocaine bingeing. These pharmacodynamic aspects are reviewed in
greater detail elsewhere in this issue.
Cocaine is rapidly eliminated from the body with a biological half-life of about one
hour and total body clearance ofabout two liters per minute [20,21,27]. Its volume of
distribution of approximately two liters per kilogram is small compared to some
psychotropic drugs. While cocaine's kinetics do show inter-individual variation, it
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appears to be less than is characteristic of many other drugs that are primarily
dependent upon microsomal oxidation for their elimination. The major hydrolytic
metabolites of cocaine, benzoylecgonine and ecgonine methyl ester, which together
comprise about 80-90 percent of a cocaine dose excreted in the urine, are eliminated
more slowly, with half-lives of about five and eight hours, respectively [6,8]. This
information regarding the kinetics and metabolic disposition ofcocaine must be taken
into account in the development, selection, and interpretation of tests used for drug
abuse screening.
ANALYSIS
The tools available for the analysis ofcocaine and its metabolites in biological fluids
are no different from those used for most other drugs. (Table 1). They include
thin-layer, gas liquid and high-performance liquid chromatography, gas chromatogra-
phy-mass spectrometry (gc/ms), and various immunoassays-both isotopic and
non-isotopic [29]. Selection of methodology for any given application must be
consistent with the nature ofcocaine's metabolic disposition and kinetics, as described
above. For example, a highly specific monoclonal antibodydirected toward unmetabol-
ized cocaine is unlikely to be of value in urine screening for cocaine abuse, as little
unchanged parent drug is excreted in the urine, and that only for a short time.
Similarly, considering cocaine's very short half-life, there would be little rationale for
the analysis ofcocaine concentrations in plasma in the evaluation ofa clinical problem
when the ingestion has occurred eight or more hours previously.
DrugAbuse Screening
As with most other drugs of abuse, one form or another of immunoassay is most
commonly used for initial screening ofurine for evidence ofcocaine use. Radioimmu-
noassay and a variety of non-isotopic immunoassays can be employed [30,31]. Drug
abuse screening provided an important and perhaps major stimulus for the develop-
ment of immunoassays for drugs and other small molecules (haptens) in general and
probably provided the major impetus for the development and refinement of non-
isotopic immunoassays. Although the antibodies used vary in specificity to some
degree, in all instances they are primarily directed at thedetection ofbenzoylecgonine,
which is the major urinary metabolite of cocaine. The widely used homogeneous
enzyme immunoassay technique, which bears the acronym EMIT®, utilizes a ligand
coupled to an enzyme, glucose-6-phosphate dehydrogenase. When used in a competi-
tive binding immunoassay, analogous to radioimmunoassay (RIA), the enzyme-ligand
conjugate that is not bound to antibody is available to act on the added substrate with
generation of NADPH. The latter can be monitored spectrophotometrically. Another
widely used type of non-isotopic assay employs fluorescence polarization. In this
instance, the ligand is conjugated to a fluorophore, and changes in fluorescent
polarization resulting from bindingoftheligand to thelarger antibody molecule can be
measured.
A variety of other ingenious non-isotopic assays for cocaine (benzoylecgonine) and
other drugs have been described. Many ofthese assays are characterized as "homoge-
neous" because, in contrast toclassical radioimmunoassay, a step to separate free from
antibody-bound ligand is not required. The marvel of these assays is that they can be
accomplished in a matter of minutes and can be automated. Thus, laboratories that
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devote themselves to drug abuse screening for cocaine, as well as other drugs, can
churn out hundreds, even thousands, of sample results per day.
It is reasonable to assume that antibodies with broad specificity that cross-react with
both major urinary metabolites of cocaine may be more sensitive and thus preferable
for drug abuse screening. For this one application, and in distinction to most assays
used for research, or for clinical purposes, narrow molecular specificity is not
necessarily an asset. On the other hand, class specificity is important. In view of the
forensic and social implications of false-positive data, it is considered axiomatic to
confirm any positive with a reference physical assay such as gas chromatography-mass
spectrometry. This dictum applies only to drug abuse screening programs. For the
rapid medical evaluation of an emergency room patient with seizures or acute
psychosis, an immunoassay for cocaine metabolites can bejustifiably used by itself.
Benzoylecgonine and ecgonine methyl ester with half-lives of about five and eight
hours, respectively, can generally be detected for up to 24 to about 48 hours after
cocaine use with the usual immunoassays [29]. Although this time period will depend
upon the amount of drug used, and possibly inter-individual differences in its
disposition, the metabolites may be detected in urine for a considerable period of time
after the acute effects of cocaine have dissipated. Their persistence following cocaine
use is, however, still relatively short compared to other drugs of abuse. For example,
drug screens may remain positive for cannabinoid metabolites for several weeks after
marijuana use in the chronic user. As with other drugs, the finding of cocaine
metabolites in urine provides no information about an individual's condition or degree
of impairment at the time of urine sampling. On the other hand, a negative urine
probably indicates that the subject has probably not used cocaine within the last two to
three days.
Cocaine, with its short half-life and relatively complete systemic metabolism,
usually disappears from the urine in four to six hours and thus is generally not the focus
of drug abuse screening. If, however, unmetabolized cocaine is detected by any of
several chromatographic methods, it is reasonable to assume that its use has been fairly
recent.
Prior to the introduction of immunoassays for drugs, thin-layer chromatography
(TLC) was the mainstay for drug abuse screening. This inexpensive, simple, yet
elegant technique has many virtues. Reactions with chromogenic reagents, sometimes
functional group-specific, provide identifying information beyond that of chromato-
graphic behavior (migration or elution time); multiple samples can be analyzed for
multiple drugs concurrently or in parallel; the appearance of parent drug with
metabolites provides characteristic patterns. In regard to cocaine, it is the only method
which can easily and concurrently demonstrate the presence of cocaine and its two
major urinary metabolites [32]. In the clinical environment, wherein other information
about the patient is available, we have found it to be a dependable way to confirm a
positive immunoassay for cocaine. Interpretation ofTLC does require experience, skill,
and some subjective judgment, not unlike other procedures and decision-making
processes in medicine. For drug abuse screening, however, when data is interpreted
absolutely and in vacuo, without clinical information, and may be used for punitive
rather than therapeutic purposes, TLC has fallen into disfavor.
While any of the common physical methods for analysis of drugs can be applied to
drug abuse screening, none are as efficient or, with the exception ofgc/ms, as sensitive
as immunoassay. It is increasingly recognized that gc/ms is the most reliable and,
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legally, the most defensible method for confirmation ofpositive immunoassays [33]. In
essence, when used in the scan mode, gc/ms can provide a molecular fingerprint of
cocaine and its metabolites. When used in the selective ion mode, considerably greater
sensitivity can be obtained, and identification is still essentially absolute if several ions
are simultaneously monitored and ratioed [34,35]. This type of analysis requires far
greater effort, skill, and time than immunoassay, and its use is commonly restricted to
confirmation. The cost-benefit ratio to society ofapplying these elegant technologies to
large-scale drug abuse screening remains to be determined.
Analysis ofCocaine in Blood
Facile analysis ofcocaine in plasma was first made possible by the introduction of a
new, highly sensitive detector for gas chromatography, the nitrogen-phosphorus
detector [36,37]. This detector responds selectively to most nitrogen-containing
compounds, with a sensitivity considerably greater than the traditional flame ioniza-
tion detector. Concentrations as low as about 5 ng/ml can be accurately quantified,
which is sufficient to determine the elimination kinetics ofcocaine after modest doses.
Currently, most assays for cocaine used in research still utilize gas chromatography
with a nitrogen detector, although gc/ms and, more recently, high-pressure liquid
chromatography are also used. As with most drug assays, gc/ms remains the state of
the art in regard to specificity. The ability to use deuterated cocaine as an internal
standard also enables unparalleled sensitivity and accuracy.
All ofthe physical assays for cocaine in plasma are considerably more complex and
difficult to perform than the immunoassays employed for drug abuse screening.
Generally, a multi-step extraction procedure is required adequately to concentrate and
separate cocaine from endogenous interferences. Research protocols, as well as clinical
and forensic studies, often fail to take into account cocaine's susceptibility to
enzymatic and alkaline hydrolysis. Blood samples must be preserved with fluoride or
another esterase inhibitor, and prolonged exposure to elevated pH must be avoided. A
significant proportion of cocaine concentrations reported in possible cases of overdose
are undoubtedly underestimated because ofthese problems.
Analysis of cocaine's major metabolites will not be discussed in detail except to
indicate that extraction and chromatography of these relatively water-soluble hydro-
lytic products is even more of a challenge than for the parent compound. Gas
chromatography and gc/ms require derivatization of the metabolites prior to chroma-
tography. Reversed-phase high-pressure liquid chromatography is particularly useful
for benzoylecgonine because a derivatization step is unnecessary [38]. Although these
metabolites are pharmacologically inactive, the presence of these more slowly elimi-
nated derivatives may be the only evidence of cocaine use at a time when the parent
compound is no longer detectable in body fluids. Aside from drug abuse screening,
investigation of cocaine metabolism may provide some insights into whether inter-
individual differences in the disposition ofcocaine may explain differences in suscepti-
bility to its toxicity.
Among the goals of current cocaine research are a better characterization of
cocaine's clinical effects and, ultimately, determination of cocaine's mechanism of
action. An understanding ofcocaine's pharmacokinetics and metabolic disposition and
the ability to quantify cocaine and its metabolites in human biological fluids are
important for the rational design and performance ofresearch at both the clinical and
basic levels. Any constructive use of drug abuse screening for cocaine requires
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absolutely accurate assays and interpretations that are consistent with current
knowledge about cocaine's kinetics and disposition.
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